Global Non-Invasive Prenatal Screening (NIPS) Market Strategic Research Report
By Type: Screening in Uncomplicated Pregnancies, Screening in High-Risk Pregnancies, Others
By Application: Public Hospitals, Private Hospitals
Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America
Key Players: Revvity, Quest Diagnostics, MedGenome, Mayo Clinic Laboratories, SYNLAB, Veritas Genetics, GGA, Cordlife, BGI Genomics, Berry Genomics, Annaroad, Genesky, Weihansi Biomedical Technology
Обзор
Scope of the Report
The global Non-Invasive Prenatal Screening (NIPS) market size is predicted to grow from US$ 3,601 million in 2025 to US$ 5,871 million in 2032; it is expected to grow at a CAGR of 7.4% from 2026 to 2032.
Non-Invasive Prenatal Screening (NIPS) is a prenatal testing method that analyzes genetic material from a pregnancy related blood sample to assess the risk of certain chromosomal or genetic conditions in the fetus without posing physical risk to the pregnancy. It is designed as a screening tool rather than a diagnostic test and is used to identify pregnancies that may benefit from further confirmatory testing and specialized clinical management.
The non invasive prenatal screening market has transitioned from a niche offering for high risk pregnancies into a mainstream component of prenatal care, driven by its strong clinical performance, low procedural risk, and growing acceptance among clinicians and expectant parents. Market dynamics are shaped by rapid technological standardization, intensifying competition, and gradual price compression, which together shift differentiation away from basic test availability toward service quality, turnaround time, reporting clarity, and integration with counseling and follow up pathways. While growth remains robust due to expanding geographic adoption and broader clinical indications, the market is increasingly influenced by reimbursement policy, ethical oversight, and evidence based guideline updates, positioning it as a mature but still structurally expanding segment within prenatal diagnostics.
This report presents a comprehensive overview of the global Non-Invasive Prenatal Screening (NIPS) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.
Segment by Type
- Screening in Uncomplicated Pregnancies
- Screening in High-Risk Pregnancies
- Others
Segment by Screening Timing
- First-trimester Screening
- Second-trimester Screening
- Late-pregnancy Screening
Segment by Service Model
- Public Health Program
- Consumer
- Others
Segment by Application
- Public Hospitals
- Private Hospitals
Who Can Use This Report?
This report is written for decision-makers who need a clear, data-backed view of the global Non-Invasive Prenatal Screening (NIPS) market:
- Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
- Distributors, channel partners and end users in Public Hospitals, Private Hospitals evaluating demand and sourcing options
- Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
- Government agencies, industry associations and research institutions tracking industry developments and policy impact
Market snapshot
Global Non-Invasive Prenatal Screening (NIPS) Market Strategic Research Report snapshot, 2025–2032
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.Segments covered in this report
Table of contents
01Executive Summary
02Industry Overview & Forecast
- 2.1.1 Market Definition and Scope
- 2.1.2 Market Size and Growth Forecast
- 2.1.3 Volume Analysis
- 2.1.4 Segment Outlook by Type
- 2.1.5 Segment Outlook by Application
- 2.1.6 Regional Outlook
- 2.1.7 Structural Developments Shaping the Forecast
- 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
- 3.1 Market Segmentation by Type
- 3.1.1 Market by Type Overview
- 3.1.2 Screening in Uncomplicated Pregnancies
- 3.1.3 Screening in High-Risk Pregnancies
- 3.1.4 Others
- 3.1.5 Volume Analysis
04Market Segmentation by Application
- 4.1 Market Segmentation by Application
- 4.1.1 Market by Application Overview
- 4.1.2 Public Hospitals
- 4.1.3 Private Hospitals
- 4.1.4 Volume Analysis
05Regional Market Forecast
- Asia Pacific
- North America
- Europe
- Middle East & Africa
- Latin America
06Country-Level Market Forecast
- 6.1 Asia Pacific
- 6.1.1 China
- 6.1.2 Japan
- 6.1.3 Korea
- 6.1.4 Southeast Asia
- 6.1.5 India
- 6.1.6 Australia
- 6.1.7 Rest of Asia Pacific
- 6.2 North America
- 6.2.1 United States
- 6.2.2 Canada
- 6.2.3 Mexico
- 6.2.4 Rest of North America
- 6.3 Europe
- 6.3.1 Germany
- 6.3.2 France
- 6.3.3 UK
- 6.3.4 Italy
- 6.3.5 Russia
- 6.3.6 Rest of Europe
- 6.4 Middle East & Africa
- 6.4.1 Egypt
- 6.4.2 South Africa
- 6.4.3 Israel
- 6.4.4 Turkey
- 6.4.5 GCC Countries
- 6.4.6 Rest of Middle East & Africa
- 6.5 Latin America
- 6.5.1 Brazil
- 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
- 7.1 Growth Drivers & Inhibitors
- 7.1.1 Section Overview
- 7.1.2 Growth Drivers
- 7.1.3 Growth Inhibitors
- 7.1.4 Driver and Inhibitor Impact Assessment
- 7.1.5 Analyst Perspective
08Key Company Profiles
- 8.1 Revvity
- 8.1.1 Company Overview
- 8.1.2 Key Products & Segments
- 8.1.3 Financial Performance (2023–2025)
- 8.1.4 Business Strategy
- 8.1.5 SWOT Analysis
- 8.1.6 Strategic Implications (2026–2032)
- 8.2 Quest Diagnostics
- 8.2.1 Company Overview
- 8.2.2 Key Products & Segments
- 8.2.3 Financial Performance (2023–2025)
- 8.2.4 Business Strategy
- 8.2.5 SWOT Analysis
- 8.2.6 Strategic Implications (2026–2032)
- 8.3 MedGenome
- 8.3.1 Company Overview
- 8.3.2 Key Products & Segments
- 8.3.3 Financial Performance (2023–2025)
- 8.3.4 Business Strategy
- 8.3.5 SWOT Analysis
- 8.3.6 Strategic Implications (2026–2032)
- 8.4 Mayo Clinic Laboratories
- 8.4.1 Company Overview
- 8.4.2 Key Products & Segments
- 8.4.3 Financial Performance (2023–2025)
- 8.4.4 Business Strategy
- 8.4.5 SWOT Analysis
- 8.4.6 Strategic Implications (2026–2032)
- 8.5 SYNLAB
- 8.5.1 Company Overview
- 8.5.2 Key Products & Segments
- 8.5.3 Financial Performance (2023–2025)
- 8.5.4 Business Strategy
- 8.5.5 SWOT Analysis
- 8.5.6 Strategic Implications (2026–2032)
- 8.6 Veritas Genetics
- 8.6.1 Company Overview
- 8.6.2 Key Products & Segments
- 8.6.3 Financial Performance (2023–2025)
- 8.6.4 Business Strategy
- 8.6.5 SWOT Analysis
- 8.6.6 Strategic Implications (2026–2032)
- 8.7 GGA
- 8.7.1 Company Overview
- 8.7.2 Key Products & Segments
- 8.7.3 Financial Performance (2023–2025)
- 8.7.4 Business Strategy
- 8.7.5 SWOT Analysis
- 8.7.6 Strategic Implications (2026–2032)
- 8.8 Cordlife
- 8.8.1 Company Overview
- 8.8.2 Key Products & Segments
- 8.8.3 Financial Performance (2023–2025)
- 8.8.4 Business Strategy
- 8.8.5 SWOT Analysis
- 8.8.6 Strategic Implications (2026–2032)
- 8.9 BGI Genomics
- 8.9.1 Company Overview
- 8.9.2 Key Products & Segments
- 8.9.3 Financial Performance (2023–2025)
- 8.9.4 Business Strategy
- 8.9.5 SWOT Analysis
- 8.9.6 Strategic Implications (2026–2032)
- 8.10 Berry Genomics
- 8.10.1 Company Overview
- 8.10.2 Key Products & Segments
- 8.10.3 Financial Performance (2023–2025)
- 8.10.4 Business Strategy
- 8.10.5 SWOT Analysis
- 8.10.6 Strategic Implications (2026–2032)
- 8.11 Annaroad
- 8.11.1 Company Overview
- 8.11.2 Key Products & Segments
- 8.11.3 Financial Performance (2023–2025)
- 8.11.4 Business Strategy
- 8.11.5 SWOT Analysis
- 8.11.6 Strategic Implications (2026–2032)
- 8.12 Genesky
- 8.12.1 Company Overview
- 8.12.2 Key Products & Segments
- 8.12.3 Financial Performance (2023–2025)
- 8.12.4 Business Strategy
- 8.12.5 SWOT Analysis
- 8.12.6 Strategic Implications (2026–2032)
- 8.13 Weihansi Biomedical Technology
- 8.13.1 Company Overview
- 8.13.2 Key Products & Segments
- 8.13.3 Financial Performance (2023–2025)
- 8.13.4 Business Strategy
- 8.13.5 SWOT Analysis
- 8.13.6 Strategic Implications (2026–2032)
09Competitive Landscape
- 9.1 Competitive Landscape Overview
- 9.2 Competitive Intensity Assessment
- 9.3 Key Player Strategies & Positioning
- 9.4 Competitive Dynamics & Strategic Outlook
- 9.4.1 Emerging Competitive Threats
- 9.4.2 Consolidation vs. Fragmentation Outlook
- 9.4.3 Competitive Response Matrix
- 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
- 10.1 Threat of New Entrants
- 10.2 Bargaining Power of Buyers
- 10.3 Bargaining Power of Suppliers
- 10.4 Threat of Substitutes
- 10.5 Competitive Rivalry
11PESTLE Analysis
- 11.1 Political
- 11.2 Economic
- 11.3 Social and Demographic
- 11.4 Technological
- 11.5 Legal and Regulatory
- 11.6 Environmental
- 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
- 13.1 Future Trends & Outlook
- 13.1.1 Trend Summary and Commercial Maturity Assessment
- 13.1.2 Technology and Innovation Trends
- 13.1.3 Long-Term Market Outlook
- 13.1.4 Investment & M&A Activity Outlook
- 13.1.5 Overall Outlook Assessment
Frequently asked questions
How big is the global Non-Invasive Prenatal Screening (NIPS) market?
How fast is the Non-Invasive Prenatal Screening (NIPS) market expected to grow?
What does the Non-Invasive Prenatal Screening (NIPS) market cover?
What are the main segments of the Non-Invasive Prenatal Screening (NIPS) market by type?
Which applications drive demand in the Non-Invasive Prenatal Screening (NIPS) market?
Who are the key players in the Non-Invasive Prenatal Screening (NIPS) market?
Which regions and countries are covered for Non-Invasive Prenatal Screening (NIPS)?
What is driving growth in the Non-Invasive Prenatal Screening (NIPS) market?
Who should buy the Non-Invasive Prenatal Screening (NIPS) market report?
What license options are available for this report?
Research Methodology
All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.
Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.
Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.
Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.
CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.
All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.
On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.
Related reports
Navadhi Market Research · Technology & SoftwareGlobal Graph Databases for Generative AI RAG Systems Market Strategic Research Report
The global market for graph databases deployed within Generative AI Retrieval-Augmented Generation (RAG) systems has emerged as one of the most consequential infrast…
Navadhi Market Research · Technology & SoftwareGlobal AI-Driven IT Service Management (AIOps-ITSM) Market Strategic Research Report
The global AI-Driven IT Service Management (AIOps-ITSM) market sits at the intersection of enterprise IT operations and artificial intelligence, addressing the inten…
Navadhi Market Research · Technology & SoftwareGlobal Enterprise LLM Orchestration Platforms Market Strategic Research Report
The global enterprise LLM orchestration platforms market has emerged as one of the most consequential segments within enterprise artificial intelligence infrastructu…
Need a customized version?
Get country-, segment- or company-specific intelligence tailored to your exact requirements.
Request custom research →Request a free sample
Receive a sample of Global Non-Invasive Prenatal Screening (NIPS) Market Strategic Research Report before you buy.
Customize This Report
Describe your specific requirements and our analysts will scope and deliver a tailored version.
Request Invoice
We will email a proforma invoice within 24 hours. Report access is granted upon payment confirmation.
Leading Brands in This Industry
